Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.67 |
| ▸ | RAF1 | P04049 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CSF1R | P07333 | 3/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255104 | 0.93 | MAPK14 (0.78) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234769 | 0.89 | FLT3 (1.00) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234771 | 0.89 | FLT3 (0.82) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234760 | 0.89 | FLT3 (0.82) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234840 | 0.88 | FLT3 (0.80) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234696 | 0.88 | FLT3 (0.80) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234704 | 0.88 | FLT3 (1.00) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234694 | 0.87 | FLT3 (0.77) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234370 | 0.87 | FLT3 (0.79) | FLT3MAPK14RAF1MEN1NPC1 | |
| SCHEMBL13234373 | 0.87 | FLT3 (1.00) | FLT3MAPK14RAF1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | FLT3 7/4885MAPK14 1436/4885RAF1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.